

# Provider Update

April 5, 2022

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H  
Infectious Disease Bureau Chief Dan Burke  
NW Regional Health Officer Miranda Durham, M.D.

# NM DOH Mission

*To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.*

## Goals



**We expand equitable access** to services for all New Mexicans



**We ensure safety** in New Mexico healthcare environments



**We improve health status** for all New Mexicans



**We support each other** by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals

# COVID-19 Overview

# Timeline:


Phases open through 1C2. Friday 3.19.21  
Self scheduling for 75+ started 3.29.21  
Self scheduling for booster doses started Thursday 4.1.21  
All phases opened Monday 4.5.21  
Self scheduling for those 60+ started Thursday 4.8.21  
Janssen pause 4.12.21  
DOH posts event code online - on purpose! For MEGA event 4.16.21  
Self scheduling for 40+ starts Monday 4.19.21  
Janssen pause lifted 4.23.21  
Homebound button implemented 4.23.21  
Self Scheduling for 16+ starts Monday 4.26.21  
Age categories change on the dashboard 4.30.21 (now tracking 65+)  
Vaccine Event Request Form implemented 5.10.21  
Pfizer EUA expanded to include children aged 12 – 15. approved by ACIP Wednesday 5.12.21  
Pfizer EUA extends vaccine storage from 5 days to 31 days in the refrigerator 5.20.21  
NM announces state-wide vaccine lottery Tuesday 6.1.21  
100\$ Incentive program for completed vaccine series Monday 6.14 – Thursday 6.17  
NMAA allows vaccinated student athletes to compete without masks - Friday 6.17  
60% fully vax declared Friday 6.18.21; reached 60% on dashboard Wednesday 6.23.21  
Texas data added to NMSIIS Tuesday 6.29.21: 22,908 first doses, 12,104 second doses and 1,260 doses of J&J.  
Dashboard changes to reporting 18+ and 12 – 17 in separate categories – Thursday 7.8.21  
Second round of \$100 incentive announced Thursday, 7.29.21 and starts Monday 8.2.21  
“Additional Dose” of mRNA vaccine approved for immunocompromised individuals by CDC – Friday 8.13.21  
FDA grants full approval to Pfizer – Monday 8.23.21  
August Incentive ends 8.31.21; opt in period ends 9.10.21  
FDA VRBPAC authorizes Pfizer boosters for 65+ and high risk – Friday 9.17.21  
CDC recommends single Pfizer booster at 6 months for certain high-risk populations 9.23.21  
Dashboard metric changed from “age at time of vax” to “age now” and federal data added to race/ethnicity metric- 10.8.21  
VRBPAC recommends Moderna and J&J boosters 10.14 - 10.15.21  
CDC authorizes Moderna, J&J and Mix&Match boosters 10.22.21  
FDA authorizes pediatric Pfizer vaccine (for ages 5 – 11) on 10.29.21  
ACIP/CDC recommends pediatric Pfizer on 11.2.21  
Boosters open to all 18+ in NM Friday 11.12.21  
FDA/ACIP approve boosters for all 18+ 11.19.21

# Timeline (cont.)

- 12.8.21** FDA authorizes AstraZeneca's Evusheld for emergency use
- 12.9.21** Pfizer boosters approved for 16 - 17-year-olds
- 12.22.21** FDA authorizes Pfizer's Paxlovid for emergency use
- 12.23.21** FDA authorizes Merck's Molnupiravir for emergency use
- 1.3.22** FDA. authorizes Pfizer vaccine boosters for everyone 12+ and expanded 3rd dose for immune compromised individuals to include 5 - 11
- 1.3.22** FDA changes booster dose time frame for Pfizer to "at least 5 months from primary series completion "
- 1.7.22** NM DOH recommends halting BAM/ETE and REGEN-COV due to high proportion of Omicron
- 1.7.22** FDA changes booster dose time frame for Moderna to "at least 5 months from primary series completion"
- 1.31.22** Moderna's SpikeVax FDA approved
- 2.4.22** Moderna's SpikeVax endorsed by ACIP and CDC
- 2.11.22** booster interval for immune compromised people chang
- 2.11.22** Bebtelovimab approved (Eli Lilly) for 12+
- 2.17.22** NM mask mandate lifted - except in healthcare, LTCF's, residential treatment centers, State prisons, juvenile justice
- 2.21.22** change to weekly vaccine reporting (on Tuesdays)
- 2.22.22** vax interval changed o allow up to 8 weeks between first and second doses
- 2.23.22** texts sent to immune compromised individuals (40K texts)
- 2.24.22** FDA amends Evusheld EUA - recommending dose increase
- 3.29.22** FDA/CDC approve a 2<sup>nd</sup> mRNA booster for 50+ and for people 12+ with immune compromise




# COMMUNITY TRANSMISSION ACROSS THE USA - for use by healthcare facilities



Community Transmission in US by County

	Total	Percent	% Change
High	433	12.23%	-0.93%
Substantial	484	13.67%	-3.45%
Moderate	1535	43.36%	-1.41%
Low	768	21.69%	5.82%

How is community transmission calculated?




[CDC COVID Data Tracker](#)

# COVID-19 Community Levels

A measure of the impact of COVID-19 illness on health and healthcare systems

## U.S. COVID-19 Community Levels by County Map

Maps, charts, and data provided by CDC, updates every Thursday by 8 pm ET  
Updated: March 17, 2022



## Cases

DAILY NEW CASES

● **4.9** PER 100K


INFECTION RATE

● **0.83**

POSITIVE TEST RATE

● **4.4%**

266



Over the last week, New Mexico has averaged 104 new confirmed cases per day (4.9 for every 100,000 residents). About this data

Share



## Cases

DAILY NEW CASES


● 4.9 PER 100K

INFECTION RATE

● 0.83

POSITIVE TEST RATE

● 4.4%



On average, each person in New Mexico with COVID is infecting 0.83 other people. Because each person is infecting fewer than one other person, the total number of current cases in New Mexico is shrinking.

Share

About this data

## Trends

METRIC


Hospitalizations

PAST # OF DAYS

All time

LOCATIONS


New Mexico



Current COVID Hospitalizations — 7 Day Average


Share

## Weekly COVID-10 Vaccines Administered in NM since 12/24/20



**BA.2 is estimated  
to be  
72% of cases per  
CDC NowCast**

updated 4/4/22



<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>



# Vaccine Updates



# FDA approves Second Dose Booster for Some Groups 3/29/22

- Adults **50 years and older** may receive a second booster dose of mRNA vaccine at least 4 months after their first booster dose (4 doses total). The second booster dose may follow any authorized or approved COVID-19 vaccine.
- Individuals **12 years and older** who are immune compromised may receive a second booster dose of an mRNA vaccine at least 4 months after their first booster dose (for a total of 5 doses). The second booster dose should be age appropriate and may follow any authorized or approved COVID-19 vaccine.
- Individuals **18 years and older** who received the Janssen vaccine and booster may receive a second booster dose of an mRNA vaccine at least 4 months after their first booster dose (for a total of 3 doses).

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

# No change in the definition of “up to date”

Updated 4/2/22

## Get Vaccinated and Stay Up to Date

A person is **fully vaccinated** two weeks after receiving all recommended doses in the primary series of their COVID-19 vaccination.

A person is **up to date** with their COVID-19 vaccination if they have received all recommended doses in the primary series and one booster when eligible. Getting a second booster is not necessary to be considered up to date at this time.

[https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html?s\\_cid=11747:cdc%20up%20to%20date%20vaccine:s em.ga:p:RG:GM:gen:PTN:FY22](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html?s_cid=11747:cdc%20up%20to%20date%20vaccine:s em.ga:p:RG:GM:gen:PTN:FY22)

# Vaccines Administered outside the USA

## Fully Vaccinated:

Am I considered fully vaccinated if I was vaccinated in another country?

You are considered fully vaccinated if you

- Received any single-dose COVID-19 vaccine series that is authorized or approved by the U.S. Food and Drug Administration (FDA) or listed for emergency use by World Health Organization (WHO).
- \*Received any combination ☐ of two doses of an FDA approved/authorized or WHO emergency use listed COVID-19 two-dose series.

Accepted COVID-19 Vaccines

	Vaccines Approved or Authorized by the U.S. Food and Drug Administration	Vaccines Listed for Emergency Use (EUL) by the World Health Organization	Certain Clinical Trial Vaccines which Have Confirmed Efficacy
Single dose	<ul style="list-style-type: none"><li>• Janssen/J&amp;J</li></ul>	<ul style="list-style-type: none"><li>• Janssen/J&amp;J</li></ul>	
2-dose series	<ul style="list-style-type: none"><li>• Pfizer-BioNTech</li><li>• Moderna</li></ul>	<ul style="list-style-type: none"><li>• Pfizer-BioNTech</li><li>• Moderna</li><li>• AstraZeneca</li><li>• Covaxin</li><li>• Covishield</li><li>• BIBP/Sinopharm</li><li>• Sinovac</li><li>• Novavax/Covovax</li></ul>	<ul style="list-style-type: none"><li>• Medicago</li></ul>

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html#fully-vaccinated-abroad-question>



**From National Immunization Program: Only a single booster dose is recommended for persons vaccinated outside the U.S. with a vaccine other than Pfizer, Moderna, or Janssen. CDC will continue to evaluate the evidence, and may issue new guidance as additional data become available. Please see below for additional information:**

## If You Were Vaccinated Outside of the United States

If you completed a Pfizer-BioNTech, Moderna, or J&J/Janssen COVID-19 vaccine primary series outside of the United States, you should follow the guidance above for boosters.

Otherwise, if you were vaccinated abroad with other COVID-19 vaccines, you can get a booster if you are 12 years or older and you either:


- Received all the recommended doses of a [World Health Organization emergency use listing \(WHO-EUL\) COVID-19 vaccineexternal icon](#), not approved or authorized by the U.S. Food and Drug Administration (FDA)
- Or completed a mix and match series composed of any combination of [FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines](#)

If you meet the above requirements, **you can get a single booster of an mRNA COVID-19 vaccine** (Pfizer-BioNTech or Moderna) at least 5 months after getting all recommended doses or completing a mix and match COVID-19 vaccine series.

# COVID-19 Vaccine Recommendations

## With Additional and Booster Doses

### mRNA Two Dose : Pfizer and Moderna Vaccine\*






# Welcome Moderna “5”

- The FDA has authorized a “booster only” formulation of the Moderna COVID-19 vaccine (dark blue cap/purple label border)
- The booster dose using this formulation is 0.5ml (50 µg)
- Moderna 5 is expected to be available mid-April
- The usual Moderna booster dose (red cap/light blue label border) remains 0.25ml (50 µg), regardless of the primary series or booster that it follows.
- Different NDC, and CPT vaccine and vaccine admin codes already assigned

<https://www.ama-assn.org/find-covid-19-vaccine-codes>

# Vaccine Watch List

- **VRBPAC meeting 4/6/22** - to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants.
- **Pfizer for 6mo - 4yo** - VRBPAC meeting postponed until May (?)
- **Moderna for kids** - press release 3/23/22:
  - 25mcg dose for 6mo - 5yo - 2 dose series
  - Study had 4,200 kids ages 2 - U6; 2,500 kids ages 6mo - 2yo
  - 38% effective for 2 - U6; 44% effective 6mo -2yo
- **Peds Pfizer for 5 - 11yo** - 3rd 10 mcg dose being studied
- **Omicron specific vaccine** - both Moderna and Pfizer studying Omicron-based vaccines
- **Novavax** - has WHO EUL - submitted request to FDA 1/31 for EUA



<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>



# How to Change Vaccine Expiration Date In NMSIIS

1. Open NMSIIS. Select Inventory > Vaccines > On-Hand. Select the 'Action' dropdown and select 'Edit'.

Vaccine Inventory On-Hand [Learn More](#)

[Add New Inventory](#) [Link](#)

Filter Options

Inventory Location: COVID TEST LOCATION Status: ON HAND

Module: Funding Source:

Location Vaccine (Brand) Mfg NDC Lot No Exp Date Funding Source Doses On-Hand Expiring Soon

COVID TEST LOCATION COVID-19 MRNA (PFIZER) COVID-19 (PURPLE CAP) 100 1000-1000-02 123ABC 04/15/2022 BLENDED 900

Showing 1 to 1 of 1 entries

2. [Vaccine Inventory Item](#) [Learn More](#)

Update

Press 'Update' once date is corrected to save change

Cancel Update

When to change your expiration date:

- Moving vaccine from one storage temp to another (ex: ULT to refrigerated)
- Expiration Dating Extensions

Please reference 'Beyond Use Date' labels when updating expiry date.

View

Inventory Location: COVID TEST LOCATION

Vaccine: COVID-19 MRNA (PFIZER)

Vacc | Mfg | NDC | Brand: COVID-19 (PFIZER) | PFIZER | 1000-1000-02 | PFIZER COVID-19 (PURPLE CAP) (1.0 X 0.5 INJ/DOSE)

Funding Source: BLENDED

Doses (Initial): 1000 Doses (Current): 900

Lot Number: 123ABC

Container Id:

Expiration Date: 04/15/2022

Org. Exp. Date: 04/15/2022

Note that modifying this inventory item will also change the following items (if applicable):

- ALL inventory transactions (e.g. adjustments and vaccinations) for the selected item
- ALL vaccination records where a dose of the selected inventory item has been administered

Clear

# How to View Depleted/Expired Inventory

**Vaccine Inventory On-Hand** [Learn More](#) [Add New Inventory](#) [Links](#)

**Filter Options**

Inventory Location: COVID TEST LOCATION  
Status: **DEPLETED/EXPIRED**  
Vaccine:   
Funding Source:   
[Filter](#)

Location	Vaccine (Brand)	Mfg	NDC	Lot No	Exp Date	Funding Source	Doses On-Hand	Expiring Soon
								<a href="#">Clear</a>
COVID TEST LOCATION - TEST	COVID TRIS-SUC (PFR 12+) (PFR COVID TRIS-SUCROSE (GREY) (10 X 8 (0.3ML/DOSE)))	PFR	59267-1025-04	12345TEST	02/01/2022	BLENDED	10	<a href="#">?</a> <a href="#">Action</a>
COVID TEST LOCATION - TEST	COVID TRIS-SUC (PFR 5-11) (PFR COVID TRIS-SUCROSE (10 X 10 (0.26ML/DOSE) MDV))	PFR	59267-1055-04	TEST1234	01/01/2022	BLENDED	0	<a href="#">?</a> <a href="#">Action</a>
COVID TEST LOCATION - TEST	COVID-19 MRNA (MOD) (MODERNA COVID-19 (10 X 10 DOSE 5.0 ML MDV))	MOD	60377-0273-99	11447798	12/13/2021	BLENDED	0	<a href="#">?</a> <a href="#">Action</a>

Showing 1 to 3 of 3 entries

Open NMSIIS. Inventory > Vaccines> On-Hand.

To view depleted/expired vaccines in NMSIIS, select the status 'Depleted/Expired' from the 'Status' dropdown and select 'Filter'.

# COVID Reconciliations MUST be completed weekly

## Opening a recon

Open NMSIIS. Select Inventory > Vaccines > Reconciliation. Select 'Add Reconciliation'.

Be sure to CLOSE your recon

If you need assistance with your COVID Recon, please reach out to:

Catherine ([Catherine.Campbell@state.nm.us](mailto:Catherine.Campbell@state.nm.us))

AND/OR

Bianca ([Bianca.Gonzales@state.nm.us](mailto:Bianca.Gonzales@state.nm.us))

You can also reach out via the NMSIIS HelpDesk:

- [COVID.vaccines@state.nm.us](mailto:COVID.vaccines@state.nm.us)
- 833-882-6454

- DATES and Time Stamps ARE IMPORTANT!!!
- Ensure that you are documenting wastage correctly (only use the reason COVID- WASTED VACCINE OTHER)
  - This includes all wastage: broken vial, expired vaccine, wasted due to missed opportunity, etc.
  - **DO NOT USE COVID-WASTED VACCINE OTHER FOR ANY REASON OTHER THAN THOSE LISTED ABOVE**
- Be sure to complete any inventory transactions before you start your recon
- If you have the option of Aggregate Administered on your recon, this is where the number of doses you administered to pts goes

# Therapeutics Update





# Sotrovimab Pause



- Sotrovimab has been found to have substantially decreased in vitro activity against the Omicron BA.2 subvariant.
- The FDA has been revoking the authorization of Sotrovimab in Health and Human Services (HHS) regions with a BA.2 sub-variant prevalence greater than 50% according to the [CDC Nowcast](#).
- The CDC Nowcast for HHS Region 6, which includes New Mexico, indicates that the prevalence of the Omicron BA.2 sub-variant is 66.7% for the week ending 4/2/2022.

# Therapeutic Management of Nonhospitalized Adults With COVID-19

Last Updated: April 1, 2022

[Nonhospitalized Adults: Therapeutic Management | COVID-19 Treatment Guidelines \(nih.gov\)](https://www.nih.gov/health-topics/coronavirus)

Figure 1. Therapeutic Management of Nonhospitalized Adults With COVID-19

PATIENT DISPOSITION	PANEL'S RECOMMENDATIONS
Does Not Require Hospitalization or Supplemental Oxygen	<p>All patients should be offered symptomatic management (AIII).</p> <p>For patients who are at high risk of progressing to severe COVID-19,<sup>a</sup> use 1 of the following treatment options:</p> <p><b>Preferred Therapies</b> <i>Listed in order of preference:</i></p> <ul style="list-style-type: none"><li>• Ritonavir-boosted nirmatrelvir (Paxlovid)<sup>b,c</sup> (AIIa)</li><li>• Remdesivir<sup>c,d</sup> (BIIa)</li></ul> <p><b>Alternative Therapies</b> <i>For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:</i></p> <ul style="list-style-type: none"><li>• Bebtelovimab<sup>e</sup> (CIII)</li><li>• Molnupiravir<sup>c,f</sup> (CIIa)</li></ul> <p>For use <b>ONLY</b> in regions where the Omicron BA.2 subvariant is not the dominant subvariant and in situations where none of the preferred or alternative options are available, feasible to use, or clinically appropriate:</p> <ul style="list-style-type: none"><li>• Sotrovimab<sup>g</sup> (CIII)</li></ul> <p>The Panel <b>recommends against</b> the use of <b>dexamethasone</b> or <b>other systemic corticosteroids</b> in the absence of another indication (AIII).<sup>h</sup></p>
Discharged From Hospital Inpatient Setting in Stable Condition and Does Not Require Supplemental Oxygen	<p>The Panel <b>recommends against</b> continuing the use of <b>remdesivir</b> (AIIa), <b>dexamethasone</b><sup>h</sup> (AIIa), or <b>baricitinib</b> (AIIa) after hospital discharge.</p>
Discharged From Hospital Inpatient Setting and Requires Supplemental Oxygen <i>For those who are stable enough for discharge but who still require oxygen<sup>i</sup></i>	<p>There is insufficient evidence to recommend either for or against the continued use of remdesivir or dexamethasone.</p>
Discharged From ED Despite New or Increasing Need for Supplemental Oxygen <i>When hospital resources are limited, inpatient admission is not possible, and close follow-up is ensured<sup>j</sup></i>	<p>The Panel recommends using <b>dexamethasone</b> 6 mg PO once daily for the duration of supplemental oxygen (dexamethasone use <b>should not</b> exceed 10 days) with careful monitoring for AEs (BIII).</p> <p>Since remdesivir is recommended for patients with similar oxygen needs who are hospitalized,<sup>k</sup> clinicians may consider using it in this setting. Given that remdesivir requires IV infusions for up to 5 consecutive days, there may be logistical constraints to administering remdesivir in the outpatient setting.</p>
<p><b>Rating of Recommendations:</b> A = Strong; B = Moderate; C = Optional <b>Rating of Evidence:</b> I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion</p>	

# Updated NIH Guideline

On April 1, 2022, the NIH updated their treatment guidelines for non hospitalized adults with COVID-19.

**Preferred therapies** in order of preference include:  
Paxlovid and Remdesivir.

**Alternative therapies** (in alphabetical order) include:  
Bebtelovimab and Molnupiravir.

**Sotrovimab:** not authorized in HHS regions where the Omicron BA.2 subvariant is the predominant variant. In regions where Sotrovimab continues to be authorized, Sotrovimab should only be utilized when none of the preferred or alternative options are available, feasible to use, or clinically appropriate.

The panel recommends against the use of dexamethasone or other systemic corticosteroids in the absence of another indication.<sup>1</sup>

Figure 1. Therapeutic Management of Nonhospitalized Adults With COVID-19

## PATIENT DISPOSITION

Does Not Require  
Hospitalization or  
Supplemental Oxygen

## PANEL'S RECOMMENDATIONS

All patients should be offered symptomatic management (AIII).

For patients who are at high risk of progressing to severe COVID-19,<sup>4</sup> use 1 of the following treatment options:

### Preferred Therapies

Listed in order of preference:

- Ritonavir-boosted nirmatrelvir (Paxlovid)<sup>1,2</sup> (AIIa)
- Remdesivir<sup>4,5</sup> (BIIa)

### Alternative Therapies

For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab<sup>6</sup> (CIII)
- Molnupiravir<sup>7,8</sup> (CIIa)

For use ONLY in regions where the Omicron BA.2 subvariant is not the dominant subvariant and in situations where none of the preferred or alternative options are available, feasible to use, or clinically appropriate:

- Sotrovimab<sup>9</sup> (CIII)

The Panel recommends against the use of dexamethasone or other systemic corticosteroids in the absence of another indication (AIII).<sup>1</sup>

# COVID19 Updates






# SARS-CoV-2 RNA Levels in Wastewater in the United States

Map Metric:

15-day percent change



SARS-CoV-2 RNA wastewater levels, United States:  
15-day percent change by sewershed

15-day % change category	Num. sites	% sites	Category change in last 7 days
-100%	9	2	13%
-99% to -10%	133	36	-42%
-9% to 0%	12	3	-48%
1% to 9%	20	5	-20%
10% to 99%	50	14	-32%
100% to 999%	93	25	8%
1000% or more	51	14	2%

Total sites with current data: 368

Total number of wastewater sampling sites: 678

[How is 15-day percent change calculated?](#)

Time Period: Mar 16, 2022 – Mar 30, 2022

Select legend categories to filter points on the map.

● -100% ● -99% to -10% ● -9% to 0% ● 1% to 9% ● 10% to 99% ● 100% to 999% ● 1000% or more ● No recent data

<https://covid.cdc.gov/covid-data-tracker/#wastewater-surveillance>


# National Wastewater Surveillance System (NWSS)



A new public health tool to understand COVID-19's spread in a community

- started September 2020
- Wastewater from a sewershed is collected as it flows into a treatment plant.
- The samples are sent to environmental or public health laboratories for SARS-CoV-2 testing.
- Health departments submit testing data to CDC through the online NWSS Data Collation and Integration for Public Health Event Response (DCIPHER) portal.
- The NWSS DCIPHER system reports results to health departments.
- Results are available to the public through [CDC's COVID Data Tracker](#).

# New Mexico



SLD developing capacity to do wastewater testing

Expected to be on line in the next 4 weeks

CDC is looking at a “panel of tests” that includes enteric pathogens

# NMED stopped wastewater surveillance operations October 2021

Collecting 24-hour composite samples: wastewater is collected at regular 15-minute intervals over 24 hours by an automatic sampling device and combined into a single composite for laboratory analysis.





# NEW COVID Quarantine and Isolation Calculator

## Quarantine and Isolation

Updated Mar. 30, 2022

Languages ▼

Print



### Quarantine and Isolation Calculator

A tool to help determine how long you need to isolate, quarantine, or take other steps to prevent spreading COVID-19.

Get Started

This information is intended for a general audience. Healthcare professionals should see [Ending Isolation and Precautions for People with COVID-19](#).

People with COVID-19 and close contacts should follow the recommendations outlined on this page. These recommendations do not change based on COVID-19 community levels.

# Daily “case counts” and hospitalizations are now on the website

## Daily Epidemiology Report

Numbers are posted Monday through Friday except on holidays.

Last Update: 4/4/2022

HOSPITALIZATIONS		DEATHS		CASES		TESTS
77 CURRENT	8 VENTILATED	14 NEW	7,293 CUMULATIVE	535 NEW	518,470 CUMULATIVE	16,209 NEW

[Epidemiology Reports | NMDOH - Coronavirus Updates \(nmhealth.org\)](https://nmhealth.org/epidemiology-reports)

# Your COVID-19 Toolkit

Resources to keep yourself and others safe from COVID-19.



## Masks

Wear a mask to protect yourself and others when you go indoors in public.

Free N95 masks are available at many local pharmacies and healthcare providers. Check with stores in your area to see where you can find free masks.

[Learn more about masks and where to get them](#)



## Vaccines

Being fully vaccinated and boosted is the best way to protect against severe illness and hospitalization from COVID-19.

[Find a vaccine or booster at vaccines.gov](#)



## Treatment

Treatments for COVID-19 are now widely available. If you test positive for COVID-19, talk to a doctor as soon as possible about [treatment options](#).

The Test-to-Treat program is one easy way to get treatment. Test-to-Treat locations will give you a test and treatment.

[Find a Test-to-Treat location near you](#)



## Testing

COVID tests can help you know if you have COVID-19 when you have symptoms, have been exposed, or are about to meet up with others.

[Order free tests](#)

Have toolkit questions?  
Call [1-800-232-0233](tel:1-800-232-0233) (TTY 1-888-720-7489)

<https://www.covid.gov/>



View this email [in your browser](#).

# LEGISLATIVE ALERT

April 5, 2022

**Senate Reaches Agreement on Bipartisan COVID-19 Supplemental Funding Bill**



# DOH Contact Information for Providers

CONTACT INFO	DESCRIPTION
<b>COVID.Vaccines@state.nm.us</b>	COVID-19 Vaccine Record requests; Provider COVID-19 Vaccine Order status; NMSIIS assistance.
<b>COVID.Therapeutics@state.nm.us</b>	Provider questions regarding COVID oral therapeutics (Molnupiravir and Paxlovid); COVID PrEP (Evusheld); mAB; or Remdesivir
<b>COVIDData.compliant@state.nm.us</b>	COVID-19 vaccine storage and handling questions, temperature log and onboarding Vaccine Plan submissions.
<b>COVID.testing-doh@state.nm.us</b>	For Provider questions on testing and test supplies

# DOH Contact Information for Patients

CONTACT INFO	DESCRIPTION
<b>COVID-19 Hotline: 1-855-600-3453</b>	Users who have questions or would like support with vaccine registration and testing
<b>ALTSD assistance: 1-800-432-2080</b>	For seniors and those with disabilities who need support with vaccine registration and scheduling.
<b>1-833-551-0518</b>	For non-health related COVID-19 questions

# Feedback on Messaging for Next Phase of the Pandemic

# A new phase of the pandemic..

- After more than 2 years of taking effective, science-based public health actions to slow the spread of COVID-19, NM has reached a new phase in the pandemic.
- The Omicron surge has passed and the spread of COVID has dramatically slowed down.
- We have learned a great deal during these two years, and most of all, we have worked together and formed many partnerships that will allow us to come together more quickly in the future.
- We now have many tools to fight COVID: testing, vaccines, therapeutics, surveillance, and emergency preparedness
- We have reached a place where NM can lift nearly all the public health requirements that prevented many COVID cases, hospitalizations and deaths; and it is now possible for us to manage COVID19 in our homes, and in our communities.



# Our Collective Work

- Administered 3,743,937 **vaccines**
- Administered 5,992,599 **COVID tests**
- Distributed over 2 million **rapid home tests**
- Deployed over 500 **staff to hospitals during surge**

# But the pandemic is not over.. even if we feel like it is

## Americans Celebrate 4th Consecutive Victory Over Covid

WASHINGTON—Gathering with family and friends to mark another effective return to normality, Americans were reportedly celebrating their fourth consecutive victory over Covid on Thursday. “Defeating the virus just once would have been enough for us, but four consecutive wins? What a treat!” said 53-year-old Indianapolis resident Adrien Miller, just one of the reported millions of people across the country who were delighted and relieved to have once again turned a corner in the battle against Covid. “We’ve absolutely dominated Covid for the fourth time in two years. How lucky are we? It’s amazing what we can accomplish in such a short time when we all work together. My heart’s just racing with the thrill of knowing I’ll never have to wear another mask for the next three months, at least.” At press time, sources confirmed Americans were raising their glasses in a toast to the next four victories.



Source: *The Onion*

<https://www.theonion.com/americans-celebrate-4th-consecutive-victory-over-covid-1848667874>

# Rapid Ag Tests and Equity

## Home test use lower in:

- People who self-identified as Black
- >75 years old
- Had lower incomes
- Had High School Education or Less

- **Reasons for getting home tests:**  
Symptoms OR Exposure Concerns
- **Rapid home tests with quarantine/ isolation and wearing a well-fitted mask** after a positive test or known exposure can help reduce the spread of COVID
- **Providing reliable and low-cost or free at-home test kits to underserved populations** with otherwise limited access to COVID-19 Testing could assisted with continued prevention efforts

[https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e1.htm?s\\_cid=mm7113e1\\_w](https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e1.htm?s_cid=mm7113e1_w)

# Finding COVID Tests in New Mexico

**Visit:** [Findatestnm.org](https://findatestnm.org) to find a COVID test in New Mexico.

**This website can show you every way** you are able to get a home test or a PCR test based off your zip code! Get a total of 9 EXTRA tests

## Find a COVID-19 Test in New Mexico.

Knowing if you have COVID-19 can help you seek proper treatment and prevent you from spreading the virus to your family and community.

Get tested if:

- You have symptoms of COVID-19: cough, fever, shortness of breath, chills, repeated shaking with chills, muscle pain, headache, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, and/or loss of taste or smell.
- You have been a close contact of someone who tested positive for COVID-19 (within 6 feet or less for more than 15 minutes).
- You are required to present a COVID-19 test to your employer, educational institution, or another entity.



To get started, please enter your information below:


ZIP CODE



# Vaccination Progress Race/Ethnicity

Hispanic/Latino, Black and African American  
Populations Amongst Lowest % Completing Primary Vaccinations


Cumulative % Completing Primary Vaccination Series, for 5 and Older



- American Indian or Alaska Native
- Asian or Pacific Islander
- Black or African American
- Hispanic or Latino
- White

Data is drawn from the New Mexico State Immunization Information System (NMSIIS) and Tiberius and includes only residents of New Mexico.

# Cumulative Percent of 5- to 11-Year-Olds Receiving First Dose



Data are drawn from the New Mexico State Immunization Information System (NMSIIS) and include only residents of New Mexico. Label shows data of 2022-03-24

# Transition to Next Phase of the Pandemic

## 1. STAY AHEAD of The Curve

Monitor for variants

Communicate COVID Alerts

Coordinate state and local response

Waste Water Monitoring

## 2. BE PREPARED

COVID is not going away

Prepared for surges

Tools, partnerships, staffing, supplies

## 3. PROVIDE TOOLS

We now have Tools to Fight Pandemic

Time for local and personal decision making

NMDOH Toolkit for Vaccines, masks, testing, meds, social distancing

Layers of Protection

## 4. PROTECT PEOPLE most Vulnerable to COVID

COVID Therapeutics

Plan for Uninsured

Support LTCF, ALF

Vaccines for 65+

Disproportionately Affected:  
High SVI, AI, Hispanic, Black

Equity Focus

## 5. SUPPORT COMMUNITIES Hardest Hit by COVID

Listen to Communities

Focus on Long Term Rebuild

Health Councils

CHWs

SVI Approach for Distributions

Tests, masks, vaccine distribution

State Health Improvement Plan (SHIP)

Better Together Funding

## 6. KEEP SCHOOLS Safe and Open

Provide information and tools

Communicate to students, staff, families

Encourage Vaccines





**THANK YOU  
for all that  
you do!**





*Investing for tomorrow, delivering today.*

1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • [nmhealth.org](http://nmhealth.org)